Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody conjugated with calicheamicin (a cytotoxic antibiotic) that is used for the treatment of acute myeloid leukemia (AML). The relationship between the CD33 expression in leukemic cells and response to GO treatment has been controversial. We studied CD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lamba, Jatinder K., Pounds, Stanley, Cao, Xueyuan, Downing, James R., Campana, Dario, Ribeiro, Raul C., Pui, Ching-Hon, Rubnitz, Jeffrey E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2659556/
https://ncbi.nlm.nih.gov/pubmed/18615103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2008.185
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados